0.5 C
Glasgow
Saturday, January 10, 2026
spot_img

More News

Small chip predicts drug side effects and acute kidney injury

Jim Cornall -
Rhabdomyolysis is a condition in which muscle damage—often caused by drug intake—can lead to impaired kidney function and acute...

Awakening dormant immune cells inside tumours to attack cancer​

Jim Cornall -
Within tumours in the human body, there are immune cells (macrophages) capable of fighting cancer, but they have been...

CRISPR screen reveals genes required for brain development and a new neurodevelopmental disorder

Jim Cornall -
An international research team has identified hundreds of genes essential for the development of brain cells, including one gene...

Osaka looks to become global life sciences hub

Jim Cornall -
With world-class research institutions, a robust industry cluster, a strong environment for international collaboration, and comprehensive business support, the...

Positive data moving breast cancer trial forward

Jim Cornall -
Swedish company Affibody AB has announced that the Trial Review Committee (TRC) has recommended to advance the phase I...

Engineering dendritic cells boosts cancer immunotherapy

Jim Cornall -
Cancer immunotherapy is a strategy that turns the patient’s own immune cells into a “search-and-destroy” force that attacks the...

Ambros Therapeutics launches with $125m to take on complex regional pain syndrome type 1

Jim Cornall -
Ambros Therapeutics, Inc. has launched as a clinical-stage biotechnology company advancing late-stage therapies for severe, underserved diseases beginning with...

ADEL and Sanofi sign $1.04bn licence agreement for Alzheimer’s therapy

Jim Cornall -
ADEL, Inc. has entered into an exclusive worldwide license agreement with Sanofi for the development and commercialization of ADEL-Y01,...

Aukera Therapeutics emerges from stealth

Jim Cornall -
Aukera Therapeutics, a preclinical-stage biotech spin-off from the University of Basel, is officially coming out of stealth as it...

FDA clears allogeneic CAR-T recurrent glioblastoma therapy for phase II trial

Jim Cornall -
T-MAXIMUM Pharmaceutical’s proprietary allogeneic B7-H3-targeted CAR-T therapy, MT027, has received IND Clearance from the U.S. Food and Drug Administration...

Platform to test new cancer treatments

Jim Cornall -
Overcoming acquired treatment resistance is one of the major challenges in the fight against cancer. While combination therapies hold promise,...

Potential biomarker for targeted psoriasis therapy discovered

Jim Cornall -
A research team led by Erwin F. Wagner from the Medical University of Vienna has discovered a previously unknown...

Base to Base biotech podcast 40: Anchored immunotherapy, and healing the skin

Jim Cornall -
This week, we’re talking about skin and wounds, with Ned Swanson, president and chief medical officer at PolarityBio, and...

Sobi boosts gout battle with Arthrosi Therapeutics acquisition

Jim Cornall -
Sobi has entered into a definitive agreement to acquire Arthrosi Therapeutics, Inc., a private late-stage biotechnology company focused on...

Immune ‘switch’ is potential target to curb chronic inflammation in cirrhosis

Jim Cornall -
Chronic liver inflammation is one of the most serious complications associated with liver cirrhosis. Researchers from Miguel Hernández University of...

InnoCare to move to phase 3 after achieving SLE endpoints

Jim Cornall -
InnoCare Pharma, which focuses on the treatment of cancer and autoimmune diseases, said the phase IIb clinical study of...

First precision therapy prostate cancer drug approved

Jim Cornall -
Johnson & Johnson says the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA)...

FDA approves generalised myasthenia gravis drug

Jim Cornall -
Amgen says the U.S. Food and Drug Administration (FDA) has approved UPLIZNA (inebilizumab-cdon) for the treatment of generalised myasthenia...

Breast cancer vaccine endpoints met with 74% immune response

Jim Cornall -
Anixa Biosciences, Inc. has announced the presentation of final data from the phase 1 clinical trial of its investigational...

Lilly to build $6bn Alabama facility

Jim Cornall -
Eli Lilly and Company has announced plans to invest more than $6bn in a new manufacturing facility in Huntsville,...

PsiThera unveiled with $47.5m funding to advance oral medicines

Jim Cornall -
PsiThera, a biotech company harnessing biologically relevant protein states and computational intelligence to create oral drugs for diseases long-constrained...

Deeptech Digest is your guide to what's new in at the cutting edge of science technology. A bit of artificial intelligence, some biotech, and all the news and latests developments in the field. If it's deeptech, it's in Deeptech Digest!

Contact us: jim@deeptechdigest.com

© 2023 Ayr Coastal Media